PIKFYVE
1-phosphatidylinositol 3-phosphate 5-kinase
As of the edition of 20 October 2026, PIKFYVE (1-phosphatidylinositol 3-phosphate 5-kinase, UniProt Q9Y2I7) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y2I7
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Digestive system; Nutrition and metabolism; Immune system; Nervous system; Blood and lymph; Cancer; Infections; Lungs and airways
- Registered trials of its drugs
- 9
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Status not established | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Apilimod | Status not established | Phase 2 | none listed |
| Apilimod | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 2 |
| Total on the list | 2 |